news
Novo Nordisk to cease distribution of Tresiba in Germany
2 July 2015 | By Victoria White
Novo Nordisk has decided to cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany...
List view / Grid view
Novo Nordisk
news
Levemir receives positive CHMP opinion for extended use in children as young as one year old
29 June 2015 | By Victoria White
The CHMP has issued a positive opinion for the expanded use of Novo Nordisk’s Levemir (insulin detemir) in children with diabetes as young as one year old...
news
Novoeight provided long-term efficacy and safety in the treatment of bleeds in people with haemophilia A
24 June 2015 | By Victoria White
Novo Nordisk announced the interim data from an extension trial of Novoeight at the International Society on Thrombosis and Haemostasis 2015 congress...
news
Xultophy Phase 3b study showed statistically significant HbA1c reduction, body weight change and lower rate of hypoglycaemia versus insulin glargine
8 June 2015 | By Victoria White
Phase 3b findings show adults with T2D treated with Xultophy demonstrate statistically significant reduction in HbA1c and a lower rate of hypoglycaemia...
news
New study with Victoza showed improvements in blood glucose control in adults with type 2 diabetes who fasted during Ramadan
8 June 2015 | By Victoria White
New findings showed that adults with type 2 diabetes treated with Victoza experienced improvements in blood glucose control while fasting during Ramadan...
news
Treatment with Saxenda for three years reduced the risk of developing type 2 diabetes
27 May 2015 | By Victoria White
The SCALE Obesity and Prediabetes trial met its primary endpoint, demonstrating that ongoing treatment with Saxenda delayed the onset of type 2 diabetes...
news
SAHF wins BMJ “Diabetes Team Of The Year” award
26 May 2015 | By Victoria White
The South Asian Health Foundation (SAHF) has been named ‘Diabetes Team of the Year’ at the prestigious 2015 BMJ Awards...
news
New data demonstrates Saxenda® (liraglutide 3 mg) provides benefits beyond weight loss
11 May 2015 | By Victoria White
Data from a post-hoc analysis of a Phase 3a trial demonstrates the weight-loss-dependent and independent effects of liraglutide 3 mg...
news
Novo Nordisk’s Changing Diabetes in Children programme extended by three years
14 April 2015 | By Victoria White
The Changing Diabetes in Children programme, a scheme that has provided free insulin to 13,000 children since 2009, has been extended by three years.
news
Novo Nordisk opens new insulin formulation and filling facility in Kaluga, Russia
13 April 2015 | By Victoria White
Novo Nordisk has opened a manufacturing facility in the Kaluga region of Russia for formulation and filling of modern insulin for the treatment of diabetes...
news
Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US
27 March 2015 | By Victoria White
Novo Nordisk has announced that it has decided to resubmit New Drug Applications of Tresiba and Ryzodeg to the FDA within the month.
news
Tresiba® (insulin degludec) approved in the EU for treatment of children and adolescents with diabetes
11 March 2015 | By Novo Nordisk
Latest data announced at Diabetes UK reinforces the long-term efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes...
news
New data shows blood glucose, CV risk factors and quality of life outcomes improvement with Saxenda®
9 March 2015 | By Novo Nordisk
New data from the phase 3a SCALE™ Obesity and Prediabetes trial were presented at The Endocrine Society’s 97th Annual Meeting (ENDO), showing that adults with obesity or who are overweight with comorbidities who had lost ≥5% of their body weight at 56 weeks (ie weight loss responders), demonstrated greater improvements…
news
Once daily treatment option made available for up to one million adult Britons with type 2 diabetes and moderate chronic kidney disease
21 January 2015 | By Aurora
A once daily injection has been approved for adults with type 2 diabetes and moderate renal impairment (stage 3 chronic kidney disease) in the UK...
news
Switzerland first country to launch Xultophy® (IDegLira)
19 January 2015 | By Novo Nordisk
Novo Nordisk announced Switzerland as the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes...
